Patiromer Sorbitex Calcium Patent Expiration

Patiromer Sorbitex Calcium is Used for lowering high levels of potassium in the blood. It was first introduced by Vifor Pharma Inc in its drug Veltassa on Oct 21, 2015.


Patiromer Sorbitex Calcium Patents

Given below is the list of patents protecting Patiromer Sorbitex Calcium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Veltassa US11123363 Potassium-binding agents for treating hypertension and hyperkalemia Oct 08, 2033 Vifor Pharma
Veltassa US9492476 Potassium-binding agents for treating hypertension and hyperkalemia Oct 08, 2033 Vifor Pharma
Veltassa US9925212 Potassium-binding agents for treating hypertension and hyperkalemia Oct 08, 2033 Vifor Pharma
Veltassa US8337824 Linear polyol stabilized polyfluoroacrylate compositions May 29, 2030 Vifor Pharma
Veltassa US8147873 Methods and compositions for treatment of ion imbalances Jun 20, 2028 Vifor Pharma
Veltassa US8282913 Ion binding polymers and uses thereof May 29, 2027 Vifor Pharma
Veltassa US8216560 Ion binding polymers and uses thereof Mar 14, 2027 Vifor Pharma
Veltassa US7556799 Ion binding polymers and uses thereof Feb 27, 2025 Vifor Pharma
Veltassa US10485821 Ion binding polymers and uses thereof Mar 30, 2024

(Expired)

Vifor Pharma
Veltassa US8287847 Ion binding polymers and uses thereof Mar 30, 2024

(Expired)

Vifor Pharma
Veltassa US8475780 Ion binding polymers and uses thereof Mar 30, 2024

(Expired)

Vifor Pharma
Veltassa US8778324 Ion binding polymers and uses thereof Mar 30, 2024

(Expired)

Vifor Pharma
Veltassa US8889115 Ion binding polymers and uses thereof Mar 30, 2024

(Expired)

Vifor Pharma



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Patiromer Sorbitex Calcium's patents.

Given below is the list recent legal activities going on the following patents of Patiromer Sorbitex Calcium.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 18 Jun, 2024 US8337824
Maintenance Fee Reminder Mailed 03 Jun, 2024 US8287847
Payment of Maintenance Fee, 12th Year, Large Entity 09 Apr, 2024 US8282913
Payment of Maintenance Fee, 12th Year, Large Entity 05 Jan, 2024 US8216560
Payment of Maintenance Fee, 12th Year, Large Entity 20 Sep, 2023 US8147873
Payment of Maintenance Fee, 4th Year, Large Entity 17 May, 2023 US10485821
Payment of Maintenance Fee, 8th Year, Large Entity 09 May, 2022 US8889115
Payment of Maintenance Fee, 8th Year, Large Entity 11 Jan, 2022 US8778324
Post Issue Communication - Certificate of Correction 25 Oct, 2021 US11123363
Payment of Maintenance Fee, 4th Year, Large Entity 22 Sep, 2021 US9925212


Patiromer Sorbitex Calcium's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List